HeartBeam has received FDA 510(k) clearance for its 12-lead ECG synthesis software for arrhythmia assessment after successfully appealing a prior NSE determination. The clearance represents a pivotal regulatory milestone for the company's cable-free cardiac monitoring technology, which captures cardiac electrical signals in three non-coplanar dimensions to generate a synthesized 12-lead electrocardiogram.
The patented technology enables patients to capture meaningful ECG data wherever symptoms occur, with the synthesized 12-lead ECG then available for remote review by a board-certified cardiologist. This addresses a critical gap in cardiac care by allowing assessment outside traditional medical facilities. With clearance secured, HeartBeam plans a limited U.S. launch in early 2026 with select cardiology groups.
The company's platform technology creates the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing these signals into a 12-lead ECG. According to the company's press release, this technology is designed for portable devices that can be used wherever the patient is located to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside medical facilities.
The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient's 3-lead ECG acquired from five electrodes. The device is intended for use by adult patients in either clinical settings or at home. The 12-Lead ECG Synthesis Software synthesizes a 12-lead ECG from the HeartBeam System's 3-lead recording device, producing a visual 12-lead ECG representation that is similar, but not identical, to the same leads of a standard diagnostic 12-lead ECG.
The synthesized 12-lead ECG output is intended for manual assessment of normal sinus rhythm and specific non-life-threatening arrhythmias including sinus arrhythmia, sinus tachycardia, sinus bradycardia, atrial premature complexes, atrial fibrillation, and ventricular premature complex. The software does not conduct cardiac analysis and is not intended to replace a standard 12-lead ECG. The company holds over 20 issued patents related to this technology enablement.
Beyond the immediate arrhythmia assessment application, HeartBeam is advancing programs in heart attack detection, development of an on-demand 12-lead extended wear patch, and the creation of AI-powered screening and prediction algorithms driven by longitudinal data from its 3D ECG platform. The company's 3D ECG technology previously received FDA clearance for arrhythmia assessment in December 2024, with the 12-Lead ECG synthesis software clearance following in December 2025.
This regulatory clearance positions HeartBeam to potentially transform cardiac care delivery by enabling remote monitoring and assessment, which could reduce healthcare costs, improve patient access to cardiac specialists, and facilitate earlier intervention for cardiac conditions. The technology's portability addresses the challenge of capturing cardiac events that often occur unpredictably outside clinical settings, potentially improving diagnostic accuracy and patient outcomes through more comprehensive data collection.
